N@N

Les Sulewski Maintained (AMRX) at Strong Buy with Increased Target to $12 on, Oct 2nd, 2024

Les Sulewski of Truist Securities, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Strong Buy with Increased Target from $10 to $12 on, Oct 2nd, 2024.

Les has made no other calls on AMRX in the last 4 months.

There are 2 other peers that have a rating on AMRX. Out of the 2 peers that are also analyzing AMRX, 1 agrees with Les's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Chris Schott of "JP Morgan" Upgraded from Sell to Hold and Held Target at $9 on, Friday, September 6th, 2024

This is the rating of the analyst that currently disagrees with Les

---

• Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $10 on, Tuesday, August 13th, 2024